Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Axsome Therapeutics "

Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD

Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.

Axsome Therapeutics | 01/07/2026 | By News Bureau

Axsome Therapeutics Secures US Food and Drug Administration Approval for Auvelity in Alzheimer's Agitation

First-in-class therapy approved to treat agitation linked to Alzheimer’s disease, addressing a major unmet need for patients and caregivers.

Axsome Therapeutics | 04/05/2026 | By News Bureau

AXS-05 by Axsome Therapeutics Advances as Novel Multimodal Therapy for CNS Disorders, Receives FDA Breakthrough Designation

Axsome Therapeutics’ investigational oral drug AXS-05 is advancing clinical development for Alzheimer’s disease agitation and smoking cessation, leveraging a unique multimodal mechanism targeting key neurotransmitter pathways.

Axsome Therapeutics | 03/01/2026 | By News Bureau | 154

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members